Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 11, Issue 9, Pages 509-524Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2014.111
Keywords
-
Categories
Funding
- Bristol-Myers Squibb
- Merck KGaA
Ask authors/readers for more resources
The therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting these responses are entering clinical practice. Antitumour immunization is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery vehicles and routes of administration are not yet identified. Active immunotherapy must also address the immunosuppressive and tolerogenic mechanisms deployed by tumours. This Review provides an overview of new results from clinical studies of therapeutic cancer vaccines directed against tumour-associated antigens and discusses their implications for the use of active immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available